We evaluated the potential diagnostic utility of PET with the cellular proliferation biomarker, 2'-deoxyl-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU), as an adjunct to multiparametric MRI (mpMRI), in localization of sites for image-guided biopsy in men with suspected prostate cancer.
Seventeen men with clinically suspected prostate cancer underwent standard mpMRI and investigational PET/CT with 18F-FMAU.
Tissue samples obtained from 22 image-guided biopsies were examined histologically. There were 11 benign, 6 ISUP grade 1, and 5 ISUP grade 2 tumors. The sensitivity for detection of ISUP 1 and ISUP 2 prostate cancer was 16.7% and 100% for mpMRI, and 50% and 60% for 18F-FMAU PET/CT, respectively.
18F-FMAU PET/CT may be a useful adjunct to mpMRI in image-guided prostate biopsy.
Clinical nuclear medicine. 2025 Feb 11 [Epub ahead of print]
Hossein Jadvar, Kai Chen, Passant Mohamed, Donya S Jadvar, Andre Luis Abreu
From the Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology., Institute of Urology, Kenneth J. Norris Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA.